4篇
您的检索式：作者名="Lingdi Zhou"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Culturing adequate CAR-T cells from less peripheral blood to treat B-cell malignancies显示文摘Objective:Chimeric antigen receptor-modified T(CAR-T)cells have shown impressive results against relapsed/refractory B cell malignancies.However,the traditional manufacture of CAR-T cells requires leukapheresis to isolate large amounts of peripheral blood T cells,thus making some patients ineligible for the procedure.Methods:We developed a simple method for CAR-T cell preparation requiring small volumes of peripheral blood.First,CD3+T cells isolated from 50 mL peripheral blood from patients(B-cell malignancies)were stimulated with immobilized anti-CD3/RetroNectin in 6-well plates and then transduced with CAR-expressing lentiviral vector.After 4 d,the T cells were transferred to culture bags for large-scale CAR-T cell expansion.In vitro and animal experiments were performed to evaluate the activity of the manufactured CAR-T cells.Finally,29 patients with B-cell acute lymphoblastic leukemia(B-ALL)and 9 patients with B-cell lymphoma were treated with the CAR-T cells.Results:The CAR-T cells were expanded to 1–3×10^(8) cells in 8–10 d and successfully killed B cell-derived malignant tumor cells in vitro and in vivo.For patients with B-ALL,the complete remission rate was 93%1 month after CAR-T cell infusion;after 12 months,the overall survival(OS)and leukemia-free survival rates were 69%and 31%,respectively.For patients with lymphoma,the objective response rate(including complete and partial remission)was 78%2 months after CAR-T cell infusion,and after 12 months,the OS and progression-free survival rates were 71%and 43%,respectively.Cytokine-release syndrome(CRS)occurred in 65.51%and 55.56%of patients with B-ALL and B-cell lymphoma,respectively;severe CRS developed in 20.69%of patients with B-ALL and in no patients with lymphoma.Conclusions:Our novel method can generate sufficient numbers of CAR-T cells for clinical use from 50–100 mL peripheral blood,thus providing an alternative means of CAR-T cell generation for patients ineligible for leukapheresis. | Lu Han Jian Zhou Linlin Li Keshu Zhou Lingdi Zhao Xinghu Zhu Qingsong Yin Yufu Li Hongqin You Jishuai Zhang Yongping Song Quanli Gao | 2021 | Cancer Biology & Medicine2021，18，4： | 2 |
| 2 | Heme oxygenase-1 is induced by thyroid hormone and involved in thyroid hormone preconditioning-induced protection against renal warm ischemia in rat显示文摘 | Fei Li Shuyan Lu Ruixia Zhu Zhongxin Zhou Lingdi Ma Leiming Cai Zhiyuan Liu | 2011 | Molecular and Cellular Endocrinology2011，，1： | 1 |
| 3 | REE geochemistry of some alkale-rich intrusive rocks in China 显示文摘 | Zhenhua Zhao Lingdi Zhou | 1997 | Science in China1997，40，2： | 1 |
| 4 | Structural state of adularia from Hishikari,Japan显示文摘Adularia sample was collected from epithermal Au-, Ag-bearing quartz-adularia veins from Hishikari, Japan. This adularia is rich in K, Or=94.63, clear, transparent, fine-grained and closely associated with quartz. In this study, it was determined by XRD, IR and 29Si, 27A1 MAS NMR methods. The adularia studied is of high sanidine with triclinic domains in it. The occupancy of Al 2t1=0.60, IR ordering θ=0.15.29Si NMR spectrum of this adularia shows a broad triplet peak, i.e. 3 poorly separated peaks at -94.9, -96.7, -99.9. This kind 29Si NMR spectrum for natural high sanidine has never been reported before. And the 27A1 NMR spectrum gives an asymmetry peak with chemical shift at 58.7 extending slightly to the low frequency. Under a violent boiling environment, Hishikari adularia rapidly crystallized from a supersaturated solution. | ZHOU Lingdi GUO Jiugao LIU Binguang LI Liyun | 2001 | Chinese Science Bulletin2001，46，11： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员